SI1965797T1 - Zmanjĺ anje omotice, neĺ˝elenega uäśinka, ki je povezan s terapijo s pirfenidonom - Google Patents

Zmanjĺ anje omotice, neĺ˝elenega uäśinka, ki je povezan s terapijo s pirfenidonom

Info

Publication number
SI1965797T1
SI1965797T1 SI200630927T SI200630927T SI1965797T1 SI 1965797 T1 SI1965797 T1 SI 1965797T1 SI 200630927 T SI200630927 T SI 200630927T SI 200630927 T SI200630927 T SI 200630927T SI 1965797 T1 SI1965797 T1 SI 1965797T1
Authority
SI
Slovenia
Prior art keywords
dizziness
reduction
side effect
pirfenidone
effect associated
Prior art date
Application number
SI200630927T
Other languages
English (en)
Slovenian (sl)
Inventor
Cynthia Y Robinson
Jeffery Stuart Loutit
Michelle M Freemer
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1965797(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of SI1965797T1 publication Critical patent/SI1965797T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
SI200630927T 2005-12-02 2006-11-29 Zmanjĺ anje omotice, neĺ˝elenega uäśinka, ki je povezan s terapijo s pirfenidonom SI1965797T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74197605P 2005-12-02 2005-12-02
PCT/US2006/045750 WO2007064738A1 (en) 2005-12-02 2006-11-29 Methods of reducing adverse events associated with pirfenidone therapy
EP06838621A EP1965797B1 (en) 2005-12-02 2006-11-29 Reduction of dizziness, a side effect associated with pirfenidone therapy

Publications (1)

Publication Number Publication Date
SI1965797T1 true SI1965797T1 (sl) 2011-03-31

Family

ID=37807840

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630927T SI1965797T1 (sl) 2005-12-02 2006-11-29 Zmanjĺ anje omotice, neĺ˝elenega uäśinka, ki je povezan s terapijo s pirfenidonom

Country Status (13)

Country Link
US (1) US20070203202A1 (OSRAM)
EP (2) EP1965797B1 (OSRAM)
JP (3) JP5175740B2 (OSRAM)
AT (1) ATE497766T1 (OSRAM)
CA (1) CA2631646C (OSRAM)
CY (1) CY1111355T1 (OSRAM)
DE (1) DE602006020070D1 (OSRAM)
DK (1) DK1965797T3 (OSRAM)
ES (2) ES2385935T3 (OSRAM)
PL (1) PL1965797T3 (OSRAM)
PT (1) PT1965797E (OSRAM)
SI (1) SI1965797T1 (OSRAM)
WO (1) WO2007064738A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
EP2124945B1 (en) * 2006-12-18 2011-04-20 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US20100190731A1 (en) * 2009-01-26 2010-07-29 Jeff Olgin Methods for treating acute myocardial infarctions and associated disorders
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2012225611B2 (en) * 2011-03-08 2016-09-15 Auspex Pharmaceuticals, Inc. Substituted N-Aryl pyridinones
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
US9517204B2 (en) 2011-09-14 2016-12-13 Shionogi & Co., Ltd. Pharmaceutical composition for inhalation
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
EP2968292A4 (en) 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2021107060A1 (ja) * 2019-11-27 2021-06-03 塩野義製薬株式会社 ピルフェニドンの副作用を軽減するための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US7867516B2 (en) 2001-01-29 2011-01-11 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
US20070032457A1 (en) * 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy

Also Published As

Publication number Publication date
EP2316453B1 (en) 2016-01-06
HK1123213A1 (en) 2009-06-12
JP2009518293A (ja) 2009-05-07
EP2316453A1 (en) 2011-05-04
JP5175740B2 (ja) 2013-04-03
HK1151726A1 (en) 2012-02-10
EP1965797A1 (en) 2008-09-10
CA2631646C (en) 2016-07-26
DK1965797T3 (da) 2011-05-02
PL1965797T3 (pl) 2011-07-29
EP1965797B1 (en) 2011-02-09
ES2385935T3 (es) 2012-08-03
JP2012229275A (ja) 2012-11-22
CA2631646A1 (en) 2007-06-07
CY1111355T1 (el) 2015-08-05
PT1965797E (pt) 2011-05-12
ATE497766T1 (de) 2011-02-15
WO2007064738A1 (en) 2007-06-07
ES2565190T3 (es) 2016-04-01
JP2015061888A (ja) 2015-04-02
DE602006020070D1 (de) 2011-03-24
US20070203202A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
CY1111355T1 (el) Μειωση της ζαλης, μια παρενεργεια που συσχετιζεται με την θεραπεια πιρφενιδονης
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
WO2006084139A8 (en) An implantable interferon-containing device
CA2404387A1 (en) Theanine compositions for promoting sleep
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008091704A3 (en) Treatment of cushing's syndrome and autism
WO2006138317A3 (en) Dosage regimen for prasugrel
EP1033133A4 (en) COMPOSITION FOR TREATING DIABETES AND METHOD FOR TREATING DIABETES
WO2007144889A3 (en) Treatment of neurofibromatosis
MX2007012991A (es) Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.
WO2007067753A3 (en) Methods of reducing side effects in cancer therapy
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
RU2002109722A (ru) Способ лечения болевого синдрома у больных хроническими соматическими заболеваниями
MXPA04006675A (es) Composicion farmaceutica que comprende glitazona y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.